Targets › ARG1
2 programs from 2 companies in 2 trials: 1 Phase 3, 1 Phase 1; Gastroenterology, Metabolic and endocrine; next expected readout Dec 2027.
Catalyzes the final step of the urea cycle by hydrolyzing L-arginine into urea, a nitrogenous waste product, and L-ornithine, a precursor to proline and polyamines; the urea cycle occurs primarily in the liver and, to a lesser extent, in the kidneys..; FUNCTION: Functions in L-arginine homeostasis in nonhepatic tissues characterized by the competition between nitric oxide synthase (NOS) and arginase for the…. (UniProt, P05089)
Open in Phaseline: the race on ARG1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Tufts University | 8% Arginine toothpaste Arginine-based toothpaste for xerostomia management | ARG1 | Phase 3 | Xerostomia | Dec 2027 |
| Rebecca Ahrens-Nicklas | LNP.UCD.ABE adenine base editor (ABE) delivered by lipid nanoparticle (LNP) for urea cycle disorder ge | CPS1, OTC, ASS1, ASL, ARG1 | Phase 1 | Urea Cycle Disorders | Sep 2028 |
Xerostomia (1) Urea Cycle Disorders (1)
small molecule (1), protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.